For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...